Huizenga Theodore Alan's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Sep 6, 2023
- Accession no.
- 0001209191-23-048489
- Filed
- Sep 6, 2023
- Trade date
- Sep 1, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $36.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Huizenga Theodore AlanCIK 0001603347 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2023 | Common Stock | SSaleDisposed | −883 | $37.04 | −$32,706.32 | 23,864 | Direct | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −87 | $38.23 | −$3,326.01 | 23,777 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.